Nothing said here yet.
to join the conversation.
First CNSide payer agreement to include CNSide’s new CSF Molecular Profile tests alongside tumor cell enumeration Expands CNSide contracted payer access to approximately 164 million covered lives HOUSTON, Oct.
New DNA and RNA tests expand CNSide beyond leptomeningeal metastases to molecular profiling across CNS oncologyHOUSTON, Oct.
Lead test on track for 200 million covered lives and beneficiaries by early 2027 after CMS meeting On track to launch expanded CNSide testing menu with multiple tests in Q4 2026 HOUSTON, Sept.
Management to provide updates on recent developments including diagnostic billing, market access & growth plansHOUSTON, Sept. 25, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Cerenome, Inc.
HOUSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Cerenome, Inc.
HOUSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), today announces the appointment of Samantha Fowlkes as Vice President Head of Commercial Sales.
Capital will support continued CNSide® commercial scale-up and development Initial tranche of funding provided at closing with future tranches linked to milestones Forecasted cash runway now into 2028 HOUSTON, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc.
HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc.
Agreement marks achievement of Cerenome’s full-year 2026 commercial payer coverage objective for CNSideHOUSTON, Aug. 13, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Cerenome, Inc.
Scalable revenue cycle ecosystem designed to support anticipated billing volumes; CNSide assay billing to begin in Q3 2026 with accumulated 2026 backlog of tests and concurrent case billingHOUSTON, Aug.
Formerly known as Plus Therapeutics, Cerenome integrates precision diagnostics, targeted therapeutics, and artificial intelligence to improve how CNS cancers are detected, treated, and understoodHOUSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc.